US Government Extends RFP-2 Contract with Bavarian Nordic
The US government has extended the RFP-2 contract that was awarded to Bavarian Nordic in 2004. Within the scope of the extension, Bavarian Nordic will initiate a larger Phase II study with IMVAMUNE® in people diagnosed with atopic dermatitis. The contract extension has a value of USD 15 million.
The additional clinical studies will be performed within the contract period, which has been extended until 2010. However the main part of the revenue is expected in the end of 2008 and beginning of 2009.
- We are very pleased that the U.S. government has decided to extend the ongoing RFP-2 contract to include clinical studies in people with atopic dermatitis, one of the potentially largest risk groups associated with traditional smallpox vaccines, says Anders Hedegaard, President & CEO of Bavarian Nordic.
He also comments that it is an important step in Bavarian Nordic's effort to develop a safe third-generation smallpox vaccine for the entire population and that it builds further on the companies long-term partnership with the U.S. government.
For further information visit the Bavarian Nordic homepage.
